Schlomo Staszewski

10.5k total citations · 2 hit papers
115 papers, 7.3k citations indexed

About

Schlomo Staszewski is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Schlomo Staszewski has authored 115 papers receiving a total of 7.3k indexed citations (citations by other indexed papers that have themselves been cited), including 100 papers in Infectious Diseases, 83 papers in Virology and 24 papers in Epidemiology. Recurrent topics in Schlomo Staszewski's work include HIV/AIDS drug development and treatment (90 papers), HIV Research and Treatment (83 papers) and HIV/AIDS Research and Interventions (56 papers). Schlomo Staszewski is often cited by papers focused on HIV/AIDS drug development and treatment (90 papers), HIV Research and Treatment (83 papers) and HIV/AIDS Research and Interventions (56 papers). Schlomo Staszewski collaborates with scholars based in Germany, United Kingdom and United States. Schlomo Staszewski's co-authors include Andrew Phillips, Jens Lundgren, Veronica Miller, Caroline Sabin, Antonella d’Arminio Monforte, Peter Reiss, Bruno Ledergerber, Dominique Costagliola, Kurt Hertogs and Margaret May and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Schlomo Staszewski

113 papers receiving 6.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

2002 1.2k citations Andrew Phillips, Bruno Ledergerber et al. The Lancet profile →
Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults

1999 788 citations Schlomo Staszewski et al. profile →

Peers

Countries citing papers authored by Schlomo Staszewski

Since Specialization

Citations

This map shows the geographic impact of Schlomo Staszewski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Schlomo Staszewski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Schlomo Staszewski more than expected).

Fields of papers citing papers by Schlomo Staszewski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Schlomo Staszewski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Schlomo Staszewski. The network helps show where Schlomo Staszewski may publish in the future.

Co-authorship network of co-authors of Schlomo Staszewski

This figure shows the co-authorship network connecting the top 25 collaborators of Schlomo Staszewski. A scholar is included among the top collaborators of Schlomo Staszewski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Schlomo Staszewski. Schlomo Staszewski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A standardized, comprehensive magnetic resonance imaging protocol for rapid and precise quantification of HIV‐1‐associated lipodystrophy 2007 ·HIV Medicine ·Markus Bickel, (unknown), Christoph Stephan, Catherine M. Crespi, Thomas A. Lutz, Stephan Klauke, (unknown), Volkmar Jacobi, (unknown), Schlomo Staszewski, Stephan Zangos	4
2	The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors 2007 ·AIDS ·Zoë Fox, Anna María Geretti, Jesper Kjær, Ulrik Bak Dragsted, Andrew Phillips, Jan Gerstoft, Schlomo Staszewski, Bonaventura Clotet, Viktor von Wyl, Jens Lundgren	16
3	First case of successful allogeneic stem cell transplantation in an HIV-patient who acquired severe Aplastic Anemia 2007 ·Haematologica ·Timo Wolf, Volker Rickerts, Schlomo Staszewski, Susanne Kriener, Barbara Waßmann, G. Bug, (unknown), Peter Gute, H.R. Brodt, Hans Martin	24
4	Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults 2007 ·European Journal of Clinical Pharmacology ·Nils von Hentig, (unknown), Annette Haberl, (unknown), Thomas A. Lutz, Schlomo Staszewski, Sebastian Harder	36
5	The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial 2006 ·The Lancet ·Joseph J. Eron, Patrick Yéni, Joseph Gathe, Vicente Estrada, Edwin DeJesus, Schlomo Staszewski, Philip Lackey, Christine Katlama, Benjamin Young, Linda Yau, Denise Sutherland‐Phillips, Paul Wannamaker, Cindy Vavro, Lisa Patel, (unknown), Mark S. Shaefer	258
6	Changes Over Time in Risk of Initial Virological Failure of Combination Antiretroviral Therapy 2006 ·Archives of Internal Medicine ·Fiona Lampe, José M. Gatell, Schlomo Staszewski, Margaret Johnson, Christian Pradier, M. John Gill, Elisa de Lazzari, (unknown), Mike Youle, Éric Fontas, Hartmut B. Krentz, Andrew Phillips	68
7	A randomized, open‐label study to compare the effects of two different doses of recombinant human growth hormone on fat reduction and fasting metabolic parameters in HIV‐1‐infected patients with lipodystrophy 2006 ·HIV Medicine ·Markus Bickel, Stephan Zangos, Volkmar Jacobi, Thomas A. Lutz, (unknown), Frank D. Goebel, Schlomo Staszewski, Stephan Klauke	11
8	A comparison of the steady‐state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy 2006 ·British Journal of Clinical Pharmacology ·Nils von Hentig, Amina Carlebach, Peter Gute, Gaby Knecht, (unknown), Maren Rohrbacher, Hartmut Stocker, Michael Kurowski, Sebastian Harder, Schlomo Staszewski, Annette Haberl	34
9	Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1 2005 ·Nature Medicine ·Gerd Fätkenheuer, Anton Pozniak, Margaret Johnson, Andreas Plettenberg, Schlomo Staszewski, Andy I. M. Hoepelman, Michael S. Saag, Frank D. Goebel, Jürgen K. Rockstroh, Bruce J. Dezube, T.M. Jenkins, (unknown), John Sullivan, Caroline E. Ridgway, Sylvie Abel, Ian James, Mike Youle, Elna van der Ryst	386
10	Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir 2004 ·AIDS ·Christoph Stephan, Nils von Hentig, Irene S. Kourbeti, (unknown), (unknown), Thomas A. Lutz, Stephan Klauke, Sebastian Harder, Michael Kurowski, Schlomo Staszewski	45
11	A 6-Base Pair Insertion in the Protease Gene of HIV Type 1 Detected in a Protease Inhibitor-Naive Patient Is Not Associated with Indinavir Treatment Failure 2003 ·AIDS Research and Human Retroviruses ·Martin Stürmer, Schlomo Staszewski, Hans Wilhelm Doerr, Kurt Hertogs	11
12	An open-label assessment of TMC 125–a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance 2003 ·AIDS ·Brian Gazzard, Anton Pozniak, (unknown), (unknown), Schlomo Staszewski, Keikawus Arastéh, (unknown), Monika Peeters, Brian Woodfall, Justin Stebbing, (unknown)	97
13	Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy 2002 ·AIDS ·Gilbert Greub, Alessandro Cozzi‐Lepri, Bruno Ledergerber, Schlomo Staszewski, Luc Perrin, Veronica Miller, P Francioli, Hansjakob Furrer, Manuel Battegay, Pietro Vernazza, Enos Bernasconi, Huldrych F. Günthard, Bernard Hirschel, Andrew Phillips, Amalio Telenti	95
14	Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA 2001 ·AIDS ·Nathan Clumeck, F. D. Goebel, Willy Rozenbaum, Jan Gerstoft, Schlomo Staszewski, (unknown), M Johnson, Brian Gazzard, Christopher Stone, (unknown), Sarah Moore	117
15	Resistance Profiles in Patients with Viral Rebound on Potent Antiretroviral Therapy 2000 ·The Journal of Infectious Diseases ·Alessandro Cozzi‐Lepri, Caroline Sabin, Schlomo Staszewski, Kurt Hertogs, Axel H. E. Müller, Holger F. Rabenau, Andrew Phillips, Veronica Miller	37
16	Dual Resistance to Zidovudine and Lamivudine in Patients Treated with Zidovudine‐Lamivudine Combination Therapy: Association with Therapy Failure 1998 ·The Journal of Infectious Diseases ·Veronica Miller, Andrew Phillips, (unknown), Schlomo Staszewski, Rudi Pauwels, Kurt Hertogs, Marie‐Pierre de Béthune, Sharon D. Kemp, Stuart Bloor, P. Richard Harrigan, Brendan Larder	74
17	HIV-1 RNA, CD4 cell count and the risk of progression to AIDS and death during treatment with HIV-1 reverse transcriptase inhibitors 1998 ·AIDS ·Schlomo Staszewski, Ralph DeMasi, Andrew Hill, (unknown)	50
18	Increased Serum and mRNA Levels of RANTES Associated with Elevated Levels of Activated CD8+CD38+ T Cells in HIV-1-Infected Individuals 1997 ·Intervirology ·(unknown), (unknown), Albrecht Werner, (unknown), Schlomo Staszewski, Veronica Miller, (unknown), Reinhard Kurth, (unknown)	16
19	Evaluation of the efficacy and tolerance of R 018893, R 089439 (loviride) and placebo in asymptomatic HIV-1-infected patients 1996 ·Antiviral Therapy ·Schlomo Staszewski, Veronica Miller, (unknown), Robert Colebunders, Bernard Vandercam, J Delescluse, Nathan Clumeck, Filip Van Wanzeele, Marc De Brabander, J. De Crée, Marc Moeremans, Koen Andries, Charles A. Boucher, Paul Stoffels, Paul A. J. Janssen	5
20	Seroprevalence of HCV, HAV, HBV, HDV, HCMV and HIV in high risk groups / Frankfurt a. M., Germany 1995 ·Zentralblatt für Bakteriologie ·Bernard Weber, Holger F. Rabenau, Annemarie Berger, E. Scheuermann, Schlomo Staszewski, W. Kreuz, I. Scharrer, (unknown), H. W. Doerr	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact